Downloads: 1
Diff of
/processing/MACCROBAT/25295501.ann
[000000]
..
[fd8900]
Switch to unified view
| a | b/processing/MACCROBAT/25295501.ann | ||
|---|---|---|---|
| 1 | T1 Age 17 28 57-year-old |
||
| 2 | T2 Sex 29 34 woman |
||
| 3 | T3 Sign_symptom 69 73 mass |
||
| 4 | E1 Sign_symptom:T3 |
||
| 5 | T4 Lab_value 51 68 rapidly enlarging |
||
| 6 | R1 MODIFY Arg1:T4 Arg2:E1 |
||
| 7 | T5 Biological_structure 81 102 left side of her neck |
||
| 8 | R2 MODIFY Arg1:T5 Arg2:E1 |
||
| 9 | T6 Date 106 110 2010 |
||
| 10 | E2 Date:T6 |
||
| 11 | T7 Therapeutic_procedure 134 147 thyroidectomy |
||
| 12 | E3 Therapeutic_procedure:T7 |
||
| 13 | T8 Detailed_description 128 133 total |
||
| 14 | R3 MODIFY Arg1:T8 Arg2:E3 |
||
| 15 | T9 Therapeutic_procedure 165 175 dissection |
||
| 16 | E4 Therapeutic_procedure:T9 |
||
| 17 | T10 Biological_structure 152 164 central neck |
||
| 18 | R4 MODIFY Arg1:T10 Arg2:E4 |
||
| 19 | T11 Distance 194 200 3.8-cm |
||
| 20 | T12 Disease_disorder 212 226 thyroid cancer |
||
| 21 | E5 Disease_disorder:T12 |
||
| 22 | T13 Detailed_description 201 211 anaplastic |
||
| 23 | R5 MODIFY Arg1:T13 Arg2:E5 |
||
| 24 | R6 MODIFY Arg1:T11 Arg2:E5 |
||
| 25 | T14 Disease_disorder 300 314 thyroid cancer |
||
| 26 | E6 Disease_disorder:T14 |
||
| 27 | T15 Detailed_description 278 299 poorly differentiated |
||
| 28 | R7 MODIFY Arg1:T15 Arg2:E6 |
||
| 29 | T16 Detailed_description 257 274 oncocytic variant |
||
| 30 | R8 MODIFY Arg1:T16 Arg2:E6 |
||
| 31 | T17 Sign_symptom 485 493 involved |
||
| 32 | E7 Sign_symptom:T17 |
||
| 33 | T18 Biological_structure 468 479 lymph nodes |
||
| 34 | T19 Lab_value 460 467 3 of 12 |
||
| 35 | R9 MODIFY Arg1:T19 Arg2:T18 |
||
| 36 | R10 MODIFY Arg1:T18 Arg2:E7 |
||
| 37 | T20 Diagnostic_procedure 423 440 Resection margins |
||
| 38 | E8 Diagnostic_procedure:T20 |
||
| 39 | T21 Lab_value 446 454 positive |
||
| 40 | #1 AnnotatorNotes T21 positive for cancer cells, specifically |
||
| 41 | R11 MODIFY Arg1:T21 Arg2:E8 |
||
| 42 | T22 Date 498 511 3 weeks after |
||
| 43 | E9 Date:T22 |
||
| 44 | T23 Diagnostic_procedure 531 544 thyroglobulin |
||
| 45 | E10 Diagnostic_procedure:T23 |
||
| 46 | T24 Detailed_description 525 530 serum |
||
| 47 | R12 MODIFY Arg1:T24 Arg2:E10 |
||
| 48 | T25 Lab_value 555 577 17.2 ng per milliliter |
||
| 49 | R13 MODIFY Arg1:T25 Arg2:E10 |
||
| 50 | T26 Diagnostic_procedure 597 621 thyroglobulin antibodies |
||
| 51 | E11 Diagnostic_procedure:T26 |
||
| 52 | T27 Lab_value 584 596 undetectable |
||
| 53 | R14 MODIFY Arg1:T27 Arg2:E11 |
||
| 54 | T28 Therapeutic_procedure 655 672 radiation therapy |
||
| 55 | E12 Therapeutic_procedure:T28 |
||
| 56 | T29 Medication 684 695 carboplatin |
||
| 57 | E13 Medication:T29 |
||
| 58 | T30 Medication 700 710 paclitaxel |
||
| 59 | E14 Medication:T30 |
||
| 60 | T31 Medication 711 723 chemotherapy |
||
| 61 | E15 Medication:T31 |
||
| 62 | R15 SUB_PROCEDURE Arg1:E14 Arg2:E15 |
||
| 63 | R16 SUB_PROCEDURE Arg1:E13 Arg2:E15 |
||
| 64 | T32 Diagnostic_procedure 735 748 thyroglobulin |
||
| 65 | E16 Diagnostic_procedure:T32 |
||
| 66 | T33 Detailed_description 729 734 serum |
||
| 67 | R17 MODIFY Arg1:T33 Arg2:E16 |
||
| 68 | T34 Date 758 771 4 weeks after |
||
| 69 | E17 Date:T34 |
||
| 70 | T35 Lab_value 829 851 12.0 ng per milliliter |
||
| 71 | R18 MODIFY Arg1:T35 Arg2:E16 |
||
| 72 | T36 Diagnostic_procedure 863 868 scans |
||
| 73 | E18 Diagnostic_procedure:T36 |
||
| 74 | T37 Date 878 892 3 months later |
||
| 75 | E19 Date:T37 |
||
| 76 | T38 Sign_symptom 927 931 mass |
||
| 77 | E20 Sign_symptom:T38 |
||
| 78 | T39 Biological_structure 909 926 right-sided hilar |
||
| 79 | R19 MODIFY Arg1:T39 Arg2:E20 |
||
| 80 | T40 Medication 998 1008 everolimus |
||
| 81 | E21 Medication:T40 |
||
| 82 | T41 Dosage 1046 1057 10 mg daily |
||
| 83 | R20 MODIFY Arg1:T41 Arg2:E21 |
||
| 84 | T42 Date 1059 1074 Within 6 months |
||
| 85 | E22 Date:T42 |
||
| 86 | T43 Diagnostic_procedure 1086 1091 scans |
||
| 87 | E23 Diagnostic_procedure:T43 |
||
| 88 | T44 Clinical_event 1076 1085 follow-up |
||
| 89 | E24 Clinical_event:T44 |
||
| 90 | T45 Coreference 1108 1114 lesion |
||
| 91 | E25 Coreference:T45 |
||
| 92 | R21 IDENTICAL Arg1:E25 Arg2:E20 |
||
| 93 | T46 Sign_symptom 1127 1145 diminished in size |
||
| 94 | E26 Sign_symptom:T46 |
||
| 95 | R22 MODIFY Arg1:E25 Arg2:E26 |
||
| 96 | T47 Area 1152 1165 3.0 by 2.6 cm |
||
| 97 | T48 Area 1169 1182 1.1 by 0.8 cm |
||
| 98 | R23 MODIFY Arg1:T47 Arg2:E26 |
||
| 99 | R24 MODIFY Arg1:T48 Arg2:E26 |
||
| 100 | T49 Duration 1200 1209 18 months |
||
| 101 | E27 Duration:T49 |
||
| 102 | T50 Sign_symptom 1225 1233 response |
||
| 103 | E28 Sign_symptom:T50 |
||
| 104 | T51 Medication 1237 1247 everolimus |
||
| 105 | E29 Medication:T51 |
||
| 106 | T52 Diagnostic_procedure 1249 1254 scans |
||
| 107 | E30 Diagnostic_procedure:T52 |
||
| 108 | T53 Disease_disorder 1264 1283 progressive disease |
||
| 109 | E31 Disease_disorder:T53 |
||
| 110 | T54 Diagnostic_procedure 1318 1333 mediastinoscopy |
||
| 111 | E32 Diagnostic_procedure:T54 |
||
| 112 | T55 Therapeutic_procedure 1339 1346 removal |
||
| 113 | E33 Therapeutic_procedure:T55 |
||
| 114 | T56 Sign_symptom 1353 1361 enlarged |
||
| 115 | E34 Sign_symptom:T56 |
||
| 116 | T57 Biological_structure 1362 1372 lymph node |
||
| 117 | R25 MODIFY Arg1:T57 Arg2:E34 |
||
| 118 | R26 MODIFY Arg1:T57 Arg2:E33 |
||
| 119 | T58 Disease_disorder 1412 1426 thyroid cancer |
||
| 120 | E35 Disease_disorder:T58 |
||
| 121 | T59 Detailed_description 1401 1411 anaplastic |
||
| 122 | T60 Detailed_description 1390 1400 metastatic |
||
| 123 | R27 MODIFY Arg1:T60 Arg2:E35 |
||
| 124 | R28 MODIFY Arg1:T59 Arg2:E35 |
||
| 125 | T61 Diagnostic_procedure 1489 1499 sequencing |
||
| 126 | E36 Diagnostic_procedure:T61 |
||
| 127 | T62 Detailed_description 1477 1488 Whole-exome |
||
| 128 | R29 MODIFY Arg1:T62 Arg2:E36 |
||
| 129 | T63 Diagnostic_procedure 1517 1523 biopsy |
||
| 130 | E37 Diagnostic_procedure:T63 |
||
| 131 | T64 Detailed_description 1539 1572 pretreatment and resistant tumors |
||
| 132 | R30 MODIFY Arg1:T64 Arg2:E37 |
||
| 133 | T65 Detailed_description 1589 1601 blood sample |
||
| 134 | R31 MODIFY Arg1:T65 Arg2:E37 |
||
| 135 | * OVERLAP E1 E2 |
||
| 136 | R32 BEFORE Arg1:E2 Arg2:E3 |
||
| 137 | * OVERLAP E3 E4 E5 E6 |
||
| 138 | R33 BEFORE Arg1:E6 Arg2:E8 |
||
| 139 | * OVERLAP E8 E7 |
||
| 140 | R34 BEFORE Arg1:E7 Arg2:E9 |
||
| 141 | * OVERLAP E9 E10 E11 |
||
| 142 | R35 BEFORE Arg1:E11 Arg2:E12 |
||
| 143 | * OVERLAP E12 E15 |
||
| 144 | R36 BEFORE Arg1:E15 Arg2:E16 |
||
| 145 | * OVERLAP E16 E17 |
||
| 146 | R37 BEFORE Arg1:E17 Arg2:E18 |
||
| 147 | * OVERLAP E18 E19 E20 E38 E21 |
||
| 148 | T66 Clinical_event 980 994 clinical trial |
||
| 149 | E38 Clinical_event:T66 |
||
| 150 | T67 Detailed_description 972 979 phase 2 |
||
| 151 | R38 MODIFY Arg1:T67 Arg2:E38 |
||
| 152 | R39 BEFORE Arg1:E21 Arg2:E22 |
||
| 153 | * OVERLAP E22 E24 E23 E25 E26 |
||
| 154 | R40 BEFORE Arg1:E26 Arg2:E27 |
||
| 155 | * OVERLAP E27 E28 E29 |
||
| 156 | R41 BEFORE Arg1:E29 Arg2:E30 |
||
| 157 | * OVERLAP E30 E31 E32 E33 E34 E35 E36 E37 |